1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials
    Meeting Abstract

    Drilon, A. E. D.; Wang, L.; Hasanovic, A.; Joubert, P.; Kris, M. G.; Riely, G. J.; Ladanyi, M.; Rizvi, N. A.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Therapeutic superiority of a TCR-like antibody to an intracellular WT1 oncogene peptide compared with the tyrosine kinase inhibitor imatinib in a mouse model of Philadelphia chromosome positive (Ph+) ALL
    Meeting Abstract

    Dubrovsky, L.; Brea, E. J.; Veomett, N. J.; Dao, T.; Yan, S.; Liu, C.; Scheinberg, D. A.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A pilot study of preoperative, single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early stage/resectable breast cancer (ESBC)
    Meeting Abstract

    Diab, A.; Solomon, S. B.; Sacchini, V.; Comstock, C.; Maybody, M.; Durack, J. C.; Sung, J. S.; Blum, B.; Neville, D. A.; Kotin, A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified liposarcoma
    Meeting Abstract

    Dickson, M. A.; Tap, W. D.; Keohan, M. L.; D'Angelo, S. P.; Gounder, M. M.; Chi, P.; Antonescu, C. R.; Landa, J.; Qin, L. X.; Rathbone, D. D.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Alliance A091103: Multicenter phase II study of the angiopoietin-1 and -2 peptibody trebananib for the treatment of angiosarcoma
    Meeting Abstract

    D'Angelo, S. P.; Mahoney, M. R.; Van Tine, B. A.; Adkins, D.; Perdekamp, M. T. G.; Condy, M. M.; Hartley, E.; Antonescu, C. R.; Schwartz, G. K.; Tap, W. D.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC)
    Meeting Abstract

    Datko, F. M.; D'Andrea, G.; Dickler, M. N.; Goldfarb, S. B.; Theodoulou, M.; Lake, D.; Fornier, M. N.; Modi, S.; Fasano, J.; Comen, E. A.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Poor prognostic features in angiosarcoma: A single institution retrospective study of 324 patients
    Meeting Abstract

    D'Angelo, S. P.; Moraco, N. H.; Qin, L. X.; Kuk, D.; Carvajal, R. D.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Antonescu, C. R.; Singer, S.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Tumor pharmacokinetics (PK) and pharmacodynamics (PD) of SAR245409 (XL765) and SAR245408 (XL147) administered as single agents to patients with recurrent glioblastoma (GBM): An Ivy Foundation early-phase clinical trials consortium study
    Meeting Abstract

    Cloughesy, T. F.; Mischel, P. S.; Omuro, A. M. P.; Prados, M.; Wen, P. Y.; Wu, B.; Rockich, K.; Xu, Y.; Lager, J. J.; Mellinghoff, I. K.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • The cytotoxicity of select neutrophils in breast cancer patients and the role of chemokines in neutrophil cytotoxicity
    Meeting Abstract

    Comen, E. A.; Granot, Z.; Blum, B.; Coker, C.; Shah, R.; Koh, E.; Norton, L.; Benezra, R.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Peripheral and tumor immune correlates in patients with advanced melanoma treated with combination nivolumab (anti-PD-1, BMS-936558, ONO-4538) and ipilimumab
    Meeting Abstract

    Callahan, M. K.; Horak, C. E.; Curran, M. A.; Hollman, T.; Schaer, D. A.; Yuan, J.; Lesokhin, A. M.; Kitano, S.; Hong, Q.; Ariyan, C. E.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save